Valentina Eberlein

Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication

R. Klopfleisch, J. Speakman, D. Görlich, 2022, iScience.

Author response for "A pair of non‐competing neutralizing human monoclonal antibodies protecting from disease in a SARS‐CoV‐2 infection model"

K. Überla, H. Jäck, S. Ciesek, 2021 .

Influence of AAV vector tropism on long-term expression and Fc-γ receptor binding of an antibody targeting SARS-CoV-2

V. Temchura, Kaveh Roshanbinfar, Leila Issmail, 2024, Communications biology.

Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

K. Überla, A. Ensser, C. Thirion, 2021, Nature Communications.

Protective mucosal immunity against SARS-CoV-2 after heterologous systemic RNA-mucosal adenoviral vector immunization

K. Überla, A. Ensser, C. Thirion, 2021, bioRxiv.

Mucosal Application of a Low-Energy Electron Inactivated Respiratory Syncytial Virus Vaccine Shows Protective Efficacy in an Animal Model

S. Ulbert, C. Hesse, Julia Finkensieper, 2023, Viruses.

Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system.

G. Golomb, J. Cinatl, A. Kannt, 2023, Journal of controlled release : official journal of the Controlled Release Society.

Mucosal immunization with a low-energy electron inactivated respiratory syncytial virus vaccine protects mice without Th2 immune bias

S. Ulbert, Julia Finkensieper, J. Fertey, 2024, Frontiers in immunology.

Orally Bioavailable RORγ/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity.

T. Dobner, Leila Issmail, Tatjana Weil, 2024, Antiviral research.